Characteristics of metabonomics and intestinal microecology in phlegm-dampened polycystic ovary syndrom

注册号:

Registration number:

ITMCTR2000003448

最近更新日期:

Date of Last Refreshed on:

2020-07-02

注册时间:

Date of Registration:

2020-07-02

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

痰湿型多囊卵巢综合征代谢组学与肠道菌群临床特征研究

Public title:

Characteristics of metabonomics and intestinal microecology in phlegm-dampened polycystic ovary syndrom

注册题目简写:

English Acronym:

研究课题的正式科学名称:

痰湿型多囊卵巢综合征代谢组学与肠道菌群临床特征研究

Scientific title:

Characteristics of metabonomics and intestinal microecology in phlegm-dampened polycystic ovary syndrom

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiCTR2000034318 ; ChiMCTR2000003448

申请注册联系人:

张晗

研究负责人:

张晗

Applicant:

Han Zhang

Study leader:

Han Zhang

申请注册联系人电话:

Applicant telephone:

+86 18322577855

研究负责人电话:

Study leader's telephone:

+86 18322577855

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

zyydxzh@163.com

研究负责人电子邮件:

Study leader's E-mail:

zyydxzh@163.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

天津市西青区昌凌路88号

研究负责人通讯地址:

天津市西青区昌凌路88号

Applicant address:

88 Changling Road, Xiqing District, Tianjin, China

Study leader's address:

88 Changling Road, Xiqing District, Tianjin, China

申请注册联系人邮政编码:

Applicant postcode:

300381

研究负责人邮政编码:

Study leader's postcode:

300381

申请人所在单位:

天津中医药大学第一附属医院

Applicant's institution:

The First Teaching Hospital of Tianjin University of Traditional Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

TYLL2020[K]字020

伦理委员会批件附件:

Approved file of Ethical Committee:

View

批准本研究的伦理委员会名称:

天津中医药大学第一附属医院医学伦理委员会

Name of the ethic committee:

IEC of the First Teaching Hospital of Tianjin University of Traditional Chinese Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2020/6/8 0:00:00

伦理委员会联系人:

贾景蕴

Contact Name of the ethic committee:

Jingyun Jia

伦理委员会联系地址:

天津市西青区昌凌路88号

Contact Address of the ethic committee:

88 Changling Road, Xiqing District, Tianjin, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 022-27986258

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

天津中医药大学第一附属医院

Primary sponsor:

The First Teaching Hospital of Tianjin University of Traditional Chinese Medicine

研究实施负责(组长)单位地址:

天津市西青区昌凌路88号

Primary sponsor's address:

88 Changling Road, Xiqing District, Tianjin, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

天津

市(区县):

Country:

China

Province:

Tianjin

City:

单位(医院):

天津中医药大学第一附属医院

具体地址:

西青区昌凌路88号

Institution
hospital:

The First Teaching Hospital of Tianjin University of Traditional Chinese Medicine

Address:

88 Changling Road, Xiqing District

经费或物资来源:

天津市教委科研计划项目 (自然科学)

Source(s) of funding:

Tianjin education commission scientific research program (natural science)

研究疾病:

多囊卵巢综合征

研究疾病代码:

Target disease:

Polycystic ovary syndrome

Target disease code:

研究类型:

Study type:

观察性研究

Observational study

研究设计:

Study design:

析因分组(即根据危险因素或暴露因素分组)

Factorial

研究所处阶段:

Study phase:

探索性研究/预试验

Pilot clinical trial

研究目的:

1.明确痰湿型PCOS患者肠道微生态特征; 2.分析痰湿型PCOS代谢组学与肠道菌群相关性。

Objectives of Study:

1. Exploring the intestinal micro-ecological characteristics of phlegm-dampness PCOS patients; 2. Analyzing the correlation between metabolomics and intestinal flora of phlegm-dampness PCOS.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

1.年龄18-40岁; 2.体重指数>23Kg/m3; 3.符合PCOS诊断; 4.符合中医辨证诊断。

Inclusion criteria

1.Aged 18-40 years; 2.Body mass index > 23Kg/m3; 3.consistent with PCOS diagnosis; 4.consistent with the diagnosis of TCM syndrome differentiation.

排除标准:

1.近三个月口服影响试验结果类药物,如抗生素、避孕药或其他激素类药物,胰岛素增敏剂,降脂药等。 2.胃肠道疾病(如:腹泻、肠炎等)或处于急性感染期等影响肠道微生态的疾病患者。 3.心、肺、肝、肾等重要脏器有器质性病变的患者或有精神疾患及其它原因不能配合试验的患者。

Exclusion criteria:

1. In the past three months, people who have taken oral drugs that affect test results, such as antibiotics, birth control pills or other hormone drugs, insulin sensitizers, lipid-lowering drugs, etc. 2. Patients suffering from gastrointestinal diseases (such as diarrhea, enteritis, etc.) or diseases affecting intestinal microecology such as acute infection. 3. Patients with organic diseases of heart, lung, liver, kidney and other important organs or patients with mental disorders and other causes that cannot cooperate with the test.

研究实施时间:

Study execute time:

From 2018-10-01

To      2021-09-30

征募观察对象时间:

Recruiting time:

From 2020-07-01

To      2021-07-01

干预措施:

Interventions:

组别:

痰湿型多囊卵巢综合征

样本量:

20

Group:

phlegm-dampened polycystic ovary syndrom

Sample size:

干预措施:

干预措施代码:

Intervention:

Nil

Intervention code:

组别:

对照组

样本量:

20

Group:

control group

Sample size:

干预措施:

干预措施代码:

Intervention:

Nil

Intervention code:

样本总量 Total sample size : 40

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

天津

市(区县):

Country:

China

Province:

tianjin

City:

单位(医院):

天津中医药大学第一附属医院

单位级别:

三级甲等

Institution/hospital:

The First Teaching Hospital of Tianjin University of Traditional Chinese Medicine

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

雄烯二酮

指标类型:

次要指标

Outcome:

androstenedione

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

尿素氮

指标类型:

副作用指标

Outcome:

Urea nitrogen

Type:

Adverse events

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

促卵泡生成素

指标类型:

次要指标

Outcome:

Follicle-stimulating hormone

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

谷丙转氨酶

指标类型:

副作用指标

Outcome:

Alanine transaminase

Type:

Adverse events

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

硫酸脱氢表雄酮

指标类型:

次要指标

Outcome:

Dehydroepiandrosterone sulfate

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肠道菌群

指标类型:

主要指标

Outcome:

Intestinal flora

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

性激素结合球蛋白

指标类型:

次要指标

Outcome:

Sex hormone binding globulin

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肌酐

指标类型:

副作用指标

Outcome:

creatinine

Type:

Adverse events

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

谷草转氨酶

指标类型:

副作用指标

Outcome:

Aspartate aminotransferase

Type:

Adverse events

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

睾酮

指标类型:

次要指标

Outcome:

testosterone

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

甘油三酯

指标类型:

次要指标

Outcome:

triglycerides

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

雌二醇

指标类型:

次要指标

Outcome:

estradiol

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血清代谢组学

指标类型:

主要指标

Outcome:

Serum metabolomics

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

高密度脂蛋白

指标类型:

次要指标

Outcome:

High density lipoprotein

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

空腹血清胰岛素

指标类型:

主要指标

Outcome:

Fasting serum insulin

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

低密度脂蛋白

指标类型:

次要指标

Outcome:

Low density lipoprotein

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

黄体生成素

指标类型:

次要指标

Outcome:

Luteinizing hormone

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

空腹葡萄糖

指标类型:

主要指标

Outcome:

Fasting glucose

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

总胆固醇

指标类型:

次要指标

Outcome:

Total cholesterol

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

粪便

组织:

Sample Name:

feces

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

标本中文名:

血清

组织:

Sample Name:

serum

Tissue:

人体标本去向

使用后保存

说明

Fate of sample 

Preservation after use

Note:

征募研究对象情况:

正在进行

Recruiting

年龄范围:

最小
Min age years
最大
Max age years

Recruiting status:

Participant age:

性别:

Gender:

女性

Female

随机方法(请说明由何人用什么方法产生随机序列):

不适用

Randomization Procedure (please state who generates the random number sequence and by what method):

N/A

盲法:

N/A

Blinding:

N/A

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

临床试验公共管理平台(www.medresman.org.cn)

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Clinical Trial Management Public Platform(www.medresman.org.cn)

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

临床指标:所有临床数据及实验室检测数据输入Excel表保存,运用SPSS18.0中文版统计软件进行分析。 代谢组学指标:数据采用Micromass MarkerLynx软件进行色谱谱峰识别以及峰匹配,用SIMCA-P软件(version11.0,Sweden)进行模式识别分析。 肠道微生态指标:QIIME software(Version 1.9.1)

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Clinical indicators: All clinical data and laboratory test data were stored in Excel and analyzed with SPSS18.0 Chinese statistical software. Metabolomics indicators: Micromass MarkerLynx software was used for chromatographic peak recognition and peak matching, and SIMCA-P software (Version11.0,Sweden) was used for pattern recognition and analysis. Intestinal Microecological Indicator :QIIME Software (Version 1.9.1)

数据管理委员会:

Data Managemen Committee:

暂未确定

Not yet

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

ITMCTR BJ-ICP:07032215-5 Tip: IE8 is recommended Use the system with widescreen display resolution above